Articles On Opthea (ASX:OPT)

Two dozen esteemed sector figures recently gathered over lunch to recount their career highs and lows One luminary recalls an uncomfortable close encounter with a drug cartel, while others overcame the impact of academic and corporate frau...

Investors are stumping up cash for life sciences capital raisings – but the stories need to be well presented After an “incredibly tumultuous” nine months, fundraisings are on track to meet last year’s bumper tally of $2.9 billion Two medt...

Highlights Uranium and mining stocks show notable short interest shifts. Industrial and education sectors experience renewed investor attention. ASX 200 stocks reflect broader market sentiment trends. This article expl...

Having satisfied the FDA about safety concerns, Neurizon will motor on to the Healey trial platform LTR Pharma invests $1 million in omega-3 side venture Thanks to options, 4D Medical cashes up   Neurizon Therapeutics (ASX:NUZ) is free to...

Pfizer has become the first Big Pharma company to sign a pricing deal with the Trump administration Bioxyne has the dope on likely US medical pot reforms Paradigm trial gets a knees-up with its first patient dosed The Trump administration...

This month’s savage reaction to Argenica Therapeutics’ (ASX:AGN) stroke drug trial results shows that investors didn’t buy management’s line that the data was “really, really positive – not just on safety, but the efficacy signals”. Argenic...

CSL shares have taken another 8% bath, even though brokers maintain valuations well above the current level Aroa Biosurgery says growing non-US sales should offset the impact of Trumpian tariffs “Opthea 2.0” is likely to stick with its kni...

Highlights Short interest sees notable shifts across energy, resources, and technology stocks Silex Systems experiences heightened attention following capital raise Liontown Resources and others show declining short positions despite...

  Highlights Boss Energy (ASX:BOE), Paladin Energy (ASX:PDN), and Pilbara Minerals (ASX:PLS) remain among the most shorted names Rising short activity observed in Silex Systems (ASX:SLX), Beach Energy (ASX:BPT), and Iluka Resour...

CSL shares tumble 12% on the back of a multi-pronged transformation drive and a perceived weak result The company is paring 3000 jobs in a bid to save up to US$550 million of annualised costs Opthea lives on!   CSL (ASX:CSL) has unveiled...

Eye drug developer Opthea’s cash balance has more than halved as the company wraps up its failed trials Poynovo shares gain 10% after a cracker full-year result Microx leads today’s sector gains after a US deal with a mystery party    The...

This article is part of the daily news updates from FNArena.com. Stay informed with the latest financial, business, and economic insights. Written by Admin Auguring well for upcoming interim results, Regal Partners has provided a positive q...

• Clarity Pharmaceuticals rocket up to 12% after its blitzkrieg placement • Artrya, Botanix and Imricor are among today’s quarterly updates • Lumos outlines US market potential   Radiopharmaceutical group Clarity Pharmaceuticals (ASX:CU6) h...

On Friday the 13th of December last year, Percheron Therapeutics (ASX:PER)  CEO Dr James Garner awaited the top-line results of the phase IIb Duchenne muscular dystrophy trial from his Brisbane lounge room. The company’s clinical developmen...

With the FDA’s blessing, Dimerix will use phase III trial endpoints that could lead to accelerated approval for its kidney disease drug Dimerix is confident of phase III success because an expert ‘peek’ at the blinded data shows it’s on th...

Bioxyne stars with a 720% gain in the 2024-25 year Paradigm shares soar 34% after $41 million convertible note deal Biotechs turn to debt funding The ASX biotech sector’s best EOFY performer has come from left field: the local and Europ...

Highlights BVF Partners exits Syntara citing fund size constraints, not program performance Trial data for myelofibrosis drug candidate shows continued progress Syntara to discuss future clinical development path with US FDA...

Arovella is one of only a handful of biotechs pursuing CAR-iNKT immunotherapies – and is the only ASX-listed exemplar The “soldiers of the blood stream”, CAR-iNKT cells offer potential advantages including easier off-the-shelf therapies Th...

As a former bus driver, Dimerix (ASX:DXB) CEO Dr Nina Webster knows that the drug development journey is just as important as the destination when it comes to delivering value to shareholders. The therapeutic trip can be painfully long, esp...

Many life science companies stress the virtue of diversity: multiple programs to protect against one of them failing. Diversity can be helpful: after its failed phase III eye disease programs, Opthea would be wishing it had another drug can...

Life science companies are turning to federal research & development tax refund advances to stave off capital raisings on unfavourable terms Biotechs undergoing eligible R&D know they will receive a federal R&D rebate, but ther...

Fund flows reveal market sentiment HUB24 and GQG crush it, and AEF holds strong Perpetual and Regal struggle but keep pushing    If you want to know what the market’s really thinking, watch the money. Fund inflows and outflows are one of...

Highlights: Orthocell lodges application for Hong Kong approval, expanding its global biotech footprint Digico REIT experiences a notable rise despite limited direct announcements Mineral Resources benefits from iron ore rec...

Good Afternoon and welcome to HotCopper’s Market Close for Thursday 10th of April, I’m Jonathon Davidson. It was a happier day for traders with a tariff reprieve from Trump who was compelled to do so by because nobody was buying US bonds...

Highlights Sayona Mining undergoes a strategic merger with Piedmont Lithium and plans a rebrand to Elevra Lithium Boss Energy shares quarterly updates at a key industry conference, drawing attention to its uranium operations...

The ASX has been up, charging 4.7% higher at around 7,720 points today. Sayona Mining (ASX:SYA) has been among the most watched on HotCopper forums on news it has merged with NASDAQ-listed Piedmont Lithium. The name of the company will b...

Troubled biotech stock Opthea (ASX:OPT), still in the process of crisis talks with investors, has flagged a workforce reduction of -65%. Listen to the HotCopper podcast for in-depth discussions and insights on all the biggest headlines...

Investors following Opthea Ltd (ASX: OPT) shares will want to know about the latest update from the business. Last month, Opthea described itself as a clinical stage biopharmaceutical company developing novel therapies to treat highly preva...

The ASX 200 has been down nearly 1% to 7,438 points after the U.S. government announced late last night it’d be pushing tariffs against China to 104%. Mineral Resources (ASX:MIN) has been among the most watched companies on the HotCopper...

Highlights  ASX faces sharp decline due to escalating US-China tariffs  Major mining and energy stocks experience significant drops  Future outlook appears cautious with potential rate cuts from RBNZ  In a striking downturn, the A...

Highlights: Short interest surged across uranium developers and producers amid sector-wide declines. James Hardie recorded a sharp uptick in short interest after a controversial acquisition. Limited short covering observed,...

This article is part of the daily news updates from FNArena.com. Stay informed with the latest financial, business, and economic insights. Written by Admin With a grim sell off in US markets on Friday, the Australian market starts the week...

ASX share Opthea Limited (ASX: OPT) remains suspended from trading as the biotech company works to avoid insolvency. Opthea last traded at 60 cents per share. Last week, we learned that Opthea has decided to cease development of...

ASX biotech share Opthea Limited (ASX: OPT) remains frozen at 60 cents apiece following a failed Phase 3 clinical trial. In an update this week, we learned that Opthea has decided to cease development of its sozinibercept (OPT-302) tr...

This article is part of the daily news updates from FNArena.com. Stay informed with the latest financial, business, and economic insights. Written by Admin Markets fell sharply on Trump tariffs and the ASX futures are pointing to ongoing se...

This article is part of the daily news updates from FNArena.com. Stay informed with the latest financial, business, and economic insights. Written by Rudi Filapek-Vandyck Through volatile day-to-day trading sessions, March proved yet anothe...

This article is part of the daily news updates from FNArena.com. Stay informed with the latest financial, business, and economic insights. Written by Admin Markets rallied overnight, and ASX futures are pointing to a rise of 0.53%, but Trum...

Highlights: Virgin Australia is advancing its plans to return to the ASX following its restructuring phase. Regulatory discussions involving ASIC continue to shape market compliance and corporate governance. Broader market m...

Welcome to this week’s HotCopper Wire, our market watch podcast! Each week, HotCopper’s senior markets reporter Jonathon Davidson and I take you through all the week’s biggest news headlines — and what they mean for Aussie investors....

The guillotines are swooshing at the FDA as a reported 3500 staff get the chop French to say ‘oui’ to fully legal medicinal cannabis Bell Potter values Opthea at 5 cents per share   Grisly tales are emerging from the corridors of the US F...

Australia’s S&P/ASX 200 records its first back-to-back monthly fall since October 2023, down 3.39% in March Ten out 11 S&P/ASX 200 sectors posted losses with utilities the only sector in the black, up 1.52% Metal Powder Works rises...

The winds of CEO change bloweth through the early commercial-stage end of the market Trial news from Neurizon and Blinklab Opthea’s latest setback brings perversely good news   The long-standing CEOs of two early commercial stage biotech...

This article is part of the daily news updates from FNArena.com. Stay informed with the latest financial, business, and economic insights. Written by Admin Month and quarter end offered some relief bottom fishing in US markets as traders te...

A ginger group of Mayne Health shareholders argues Cosette’s $600 million offer isn’t the right prescription Artrya gets to the heart of the matter after FDA approval Zelira Therapeutics goes to the ATM for $1 million   US healthcare grou...

Highlights: Regal Partners Ltd, an alternative investment manager, experienced significant share price movements throughout the week. A substantial decline occurred following developments related to Opthea Limited, a company in w...

ASX heath sector falls 2.1%, while broader markets rise 0.8% for the same period Opthea phase III Coast trial into wet AMD fails to meet primary and secondary endpoints  EMVision starts pivotal validation trial for emu bedside brain scanne...

ASX All Ords dividend stock Regal Partners Ltd (ASX: RPL) is having a wild ride this week. Shares in the All Ordinaries Index (ASX: XAO) listed alternative investment manager closed down 8.85% on Thursday at $2.37. That followed on a gain o...

Despite a late upturn, the ASX 200 closed 0.38% in the red on Thursday Blame factor 1: Trump and his 25% US auto import tariffs, set to come into play early April Blame factor 2: A Wall Street tech rout, which Trump had a hand in, too   ...

Welcome to this week’s HotCopper Wire, our market watch podcast! Each week, HotCopper’s senior markets reporter Jonathon Davidson and I take you through all the week’s biggest news headlines — and what they mean for Aussie investors....

Highlights S&P/ASX 200 (ASX:XJO) breaches 8,000 mark, buoyed by cooling inflation. Robust gains in energy and mining sectors as commodity prices rally. Tuas (ASX:TUA) faces a sharp decline despite reporting a profitable half-year....